Showing results (31-40 of 53) with videos related to
Sort By:
Pageof 6
FEBS Letters|August 2, 2012
A687V EZH2 is a gain-of-function mutation found in lymphoma patientsChristina R Majer, Lei Jin, Margaret Porter Scott, et al.North Carolina Medical Journal|February 4, 2014
A renaissance in pharmacy education at the University of North Carolina at Chapel HillMary T Roth, Russell J Mumper, Scott F Singleton, et al.SLAS Discovery : Advancing Life Sciences R & D|December 20, 2019
Forced Self-Modification Assays as a Strategy to Screen MonoPARP EnzymesTim J Wigle, W David Church, Christina R Majer, et al.ACS Chemical Biology|August 26, 2014
Reaction coupling between wild-type and disease-associated mutant EZH2Brooke M Swalm, Sarah K Knutson, Natalie M Warholic, et al.Journal of Biomolecular Screening|March 11, 2015
A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase ScreeningTim J Wigle, Kerren K Swinger, John E Campbell, et al.Proceedings of the National Academy of Sciences of the United States of America|April 27, 2013
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Sarah K Knutson, Natalie M Warholic, Tim J Wigle, et al.Journal of Medicinal Chemistry|January 16, 2016
The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of TazemetostatKevin W Kuntz, John E Campbell, Heike Keilhack, et al.Chemical Biology & Drug Design|September 18, 2012
Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1LAravind Basavapathruni, Lei Jin, Scott R Daigle, et al.Plos One|May 10, 2018
Identification of a peptide inhibitor for the histone methyltransferase WHSC1Michael J Morrison, P Ann Boriack-Sjodin, Kerren K Swinger, et al.Journal of Medicinal Chemistry|March 23, 2011
Small-molecule ligands of methyl-lysine binding proteinsJ Martin Herold, Tim J Wigle, Jacqueline L Norris, et al.Pageof 6